Designing Fluoroquinolone Breakpoints for Streptococcus pneumoniae by Using Genetics instead of Pharmacokinetics-Pharmacodynamics
| Autor: | C. G. Siemens, Ayman M. Noreddin, George G. Zhanel, Chris J. Hoban, Daryl J. Hoban, J. Greisman, Kristen N. Schurek, Heather J. Smith |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
DNA
Bacterial Ofloxacin Gemifloxacin Moxifloxacin Levofloxacin Microbial Sensitivity Tests Biology medicine.disease_cause Gatifloxacin Microbiology Drug Resistance Bacterial Streptococcus pneumoniae medicine Pharmacology (medical) Antibacterial agent Pharmacology Genetics Aza Compounds Dose-Response Relationship Drug Reverse Transcriptase Polymerase Chain Reaction Virology Anti-Bacterial Agents DNA Topoisomerases Type II Infectious Diseases Susceptibility Pharmacodynamics Mutation Quinolines Monte Carlo Method Fluoroquinolones medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 48:3630-3635 |
| ISSN: | 1098-6596 0066-4804 |
| Popis: | We determined fluoroquinolone microbiological resistance breakpoints for Streptococcus pneumoniae by using genetic instead of pharmacokinetic-pharmacodynamic parameters. The proposed microbiological breakpoints define resistance as the MIC at which >50% of the isolates carry quinolone resistance-determining region mutations and/or, if data are available, when Monte Carlo simulations demonstrate a 0.25; gemifloxacin, >0.03; levofloxacin, >1; and moxifloxacin, >0.12. Monte Carlo simulations of the once daily 400-mg doses of gatifloxacin and 750-mg doses levofloxacin demonstrated a high level of target attainment (free-drug area under the concentration-time curve from 0 to 24 h/MIC ratio of 30) by using these new genetically derived breakpoints. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|